Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An artist's rendering of lipidoid-siRNA delivery nanoparticles. Akinc et al. (p 561) describe the development of a combinatorial library of new lipidlike materials for the delivery of RNAi therapeutics. Credit: Scott Dixon.
Amgen's retrospective sortie into personalized Vectibix treatment poses some difficult questions for regulators concerning the oversight of companion diagnostics.
The special protocol assessment introduced only six years ago by the US Food and Drug Administration (FDA) to facilitate clinical trials is gaining popularity. Randy Osborne finds out why.
It's no gold rush, but dozens of players are emerging in personalized medicine, with biotechs, big and small, leading the way. Some big pharma companies and even payers remain skeptical, but economics aside, the real winners will be patients.
